Barclays »

Gain Therapeutics shares owned by Barclays

Quarter-by-quarter ownership of Gain Therapeutics (GANX) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Gain Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Gain Therapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Gain Therapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2026-06-30 $2.7k 1.4k 2.03

More positions owned by Barclays

STATE STR SPDR S&ampP 500 ETF T Fund (SPY)
Ishares Tr Opt Call Option (EEM)
Microsoft Corp Opt Call Option (MSFT)
Invesco Qqq Tr Fund (QQQ)
Ishares Tr Fund (IWM)
Nvidia Corporation Opt Call Option (NVDA)
Micron Technology (MU)
Apple (AAPL)
Alphabet Inc Class A cs (GOOGL)
Amazon Opt Put Option (AMZN)
Vaneck Etf Trust Opt Put Option (SMH)
Tesla Motors (TSLA)
Advanced Micro Devices Opt Put Option (AMD)
Broadcom Opt Put Option (AVGO)
Ishares Tr Opt Call Option (HYG)

View all positions for Barclays

Top funds holding Gain Therapeutics

Marshall Wace
Potomac Capital Management
GSA Capital Partners
Jones Financial Companies, L.L
Cambridge Investment Research Advisors
DME Capital Management
Vanguard Capital Management
Geode Capital Management
BlackRock
Vanguard Fiduciary Trust
UBS Group
Stratos Wealth Partners
Citadel Advisors
Cresset Asset Management
State Street Corporation

View all funds holding Gain Therapeutics